Valuation: Valion Bio, Inc.

Market Cap 2.72M 2.33M 2.18M 2M 3.75M 260M 3.8M 25.76M 10.05M 131M 10.22M 9.99M 432M P/E 2024
-0.3x
P/E 2025 -0.19x
Enterprise Value -3.47M -2.97M -2.78M -2.55M -4.78M -332M -4.84M -32.86M -12.82M -167M -13.03M -12.75M -552M EV / Sales 2024
1.64x
EV / Sales 2025 -
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 day+19.09%
1 week-28.77%
Current month-58.06%
1 month-56.23%
3 months-85.09%
6 months-82.90%
Current year-91.03%
1 week 0.11
Extreme 0.1116
0.18
1 month 0.11
Extreme 0.1116
1.3
Current year 0.11
Extreme 0.1116
1.5
1 year 0.11
Extreme 0.1116
3.21
3 years 0.11
Extreme 0.1116
68.17
5 years 0.11
Extreme 0.1116
11,050.01
10 years 0.11
Extreme 0.1116
11,050.01
Manager TitleAgeSince
Chief Executive Officer 55 2026-03-02
Director of Finance/CFO 63 2024-09-30
Compliance Officer - 2025-12-31
Director TitleAgeSince
Chairman 79 2021-08-17
Director/Board Member 58 2019-07-09
Director/Board Member 70 2024-06-30
Date Insider Type Main position Quantity % Market Cap.
5/18/26 Fiscal year

Chief Executive Officer

4,412 0.1533%
2/18/26 Fiscal year

Chief Executive Officer

17,648 0.6987%
12/18/25 Fiscal year

Chief Executive Officer

34,674 1.9635%
Change 5-day change 1-year change 3-year change Capi.($)
+16.64%-28.77%-95.91%-99.71% 2.72M
-1.42%+6.63%+27.21%+16.04% 233B
-1.01%+7.67%+5.02%-13.96% 154B
-0.31%-3.11%-19.27%+32.40% 134B
-2.29%-4.12%-53.09%-2.22% 73B
+0.66%+3.97%-14.70%-11.31% 52.24B
+0.65%-0.45%+11.80%+20.52% 51.75B
-2.50%+5.10%+30.94%+30.57% 44.91B
-0.88%+0.55%+37.14%+51.19% 40.35B
-0.83%+3.07%+0.01%+9.01% 33.8B
Average +1.11%-1.89%-7.08%+3.25% 81.64B
Weighted average by Cap. -0.99%+3.06%+4.14%+12.22%

Financials

2024 2025
Net sales 780K 668K 625K 572K 1.07M 74.63M 1.09M 7.39M 2.88M 37.49M 2.93M 2.87M 124M -
Net income -5.66M -4.84M -4.53M -4.15M -7.79M -541M -7.89M -53.55M -20.88M -272M -21.23M -20.77M -899M -8.88M -7.6M -7.12M -6.51M -12.22M -849M -12.39M -84.07M -32.78M -427M -33.34M -32.61M -1.41B
Net Debt -2M -1.71M -1.6M -1.47M -2.76M -192M -2.79M -18.96M -7.39M -96.22M -7.52M -7.35M -318M -6.19M -5.3M -4.96M -4.54M -8.52M -592M -8.64M -58.63M -22.86M -298M -23.25M -22.74M -984M
Logo Valion Bio, Inc.
Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.
Employees
-
Date Price Change Volume
26-08-24 US$0.1302 +6.20% 16,864,773
26-08-21 US$0.1226 +0.41% 3,906,050
26-08-20 US$0.1221 -9.15% 4,999,393
26-08-19 US$0.1344 -16.31% 12,427,505
26-08-18 US$0.1606 -12.00% 10,776,249
  1. Stock Market
  2. Stocks
  3. VBIO Stock